{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T02:25:47Z","timestamp":1694399147365},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T00:00:00Z","timestamp":1286323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10147-010-0134-x","type":"journal-article","created":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T04:40:19Z","timestamp":1286253619000},"page":"118-124","source":"Crossref","is-referenced-by-count":6,"title":["Usage of granulocyte colony-stimulating factor every 2\u00a0days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Yoshihiro","family":"Yakushijin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaharu","family":"Shikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikue","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamami","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Hato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,6]]},"reference":[{"key":"134_CR1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJM199207023270106","volume":"327","author":"GJ Lieschke","year":"1992","unstructured":"Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Eng J Med 327:28\u201335","journal-title":"N Eng J Med"},{"key":"134_CR2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/infdis\/163.3.579","volume":"163","author":"E Roilides","year":"1991","unstructured":"Roilides E, Walsh TJ, Pizzo PA et al (1991) Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 163:579\u2013583","journal-title":"J Infect Dis"},{"key":"134_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0161-5890(90)90060-D","volume":"27","author":"DV Erbe","year":"1990","unstructured":"Erbe DV, Collins JE, Shen L et al (1990) The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells. Mol Immunol 27:57\u201360","journal-title":"Mol Immunol"},{"key":"134_CR4","first-page":"606","volume":"82","author":"G Carulli","year":"1997","unstructured":"Carulli G (1997) Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions. Haematologica 82:606\u2013616","journal-title":"Haematologica"},{"key":"134_CR5","first-page":"83","volume":"3","author":"B Rouveix","year":"2001","unstructured":"Rouveix B, Giroud JP, Levacher M (2001) G-CSF: mode of action and antiinfective activities. Antibiotiques 3:83\u201389","journal-title":"Antibiotiques"},{"key":"134_CR6","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendation for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"134_CR7","doi-asserted-by":"crossref","unstructured":"Pettengell R, Aapro M, Brusamolino E et al (2009) Implications of the European Organisation for Research and Treatment of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. Clin Drug Invest 29:491\u2013513","DOI":"10.2165\/00044011-200929080-00001"},{"key":"134_CR8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1365-2141.1997.2393053.x","volume":"98","author":"MJ Watts","year":"1997","unstructured":"Watts MJ, Addison I, Long SG et al (1997) Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 98:474\u2013479","journal-title":"Br J Haematol"},{"key":"134_CR9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003495-200059030-00017","volume":"59","author":"CJ Dunn","year":"2000","unstructured":"Dunn CJ, Goa KL (2000) Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 59:681\u2013717","journal-title":"Drugs"},{"key":"134_CR10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1185\/030079903125002531","volume":"19","author":"IH Kim","year":"2003","unstructured":"Kim IH, Park SK, Suh OK et al (2003) Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Curr Med Res Opinion 19:753\u2013759","journal-title":"Curr Med Res Opinion"},{"key":"134_CR11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ajh.21206","volume":"83","author":"S Ataergin","year":"2008","unstructured":"Ataergin S, Arpaci F, Turan M et al (2008) Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 83:644\u2013648","journal-title":"Am J Hematol"},{"key":"134_CR12","doi-asserted-by":"crossref","unstructured":"Welte K, Gabrilove J, Bronchud MH et al (1996) Filgrastim (r-metHuG-CSF): the first 10\u00a0years. Blood 15:1907\u20131929","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907"},{"key":"134_CR13","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/blood.V82.11.3265.3265","volume":"82","author":"JM Kerst","year":"1993","unstructured":"Kerst JM, de Haas M, van der Schoot CE et al (1993) Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 82:3265\u20133272","journal-title":"Blood"},{"key":"134_CR14","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","volume":"12","author":"L Balducci","year":"2007","unstructured":"Balducci L, Al-Halawani H, Charu V et al (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12:1416\u20131424","journal-title":"Oncologist"},{"key":"134_CR15","first-page":"109","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer NM et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. JNCCN 6:109\u2013118","journal-title":"JNCCN"},{"key":"134_CR16","first-page":"99","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. JNCCN 7:99\u2013108","journal-title":"JNCCN"},{"key":"134_CR17","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","volume":"22","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Dale DC, Friedberg J et al (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: a nationwide study. J Clin Oncol 22:4302\u20134311","journal-title":"J Clin Oncol"},{"key":"134_CR18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.20.3.727","volume":"20","author":"A Holmes","year":"2002","unstructured":"Holmes A, O\u2019Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20:727\u2013731","journal-title":"J Clin Oncol"},{"key":"134_CR19","doi-asserted-by":"crossref","unstructured":"Green MD, Koelbl H, Baselga J et al (2003) A randomized doubleblind multicenter phase III study of fixed-dose single administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335","DOI":"10.1093\/annonc\/mdg019"},{"key":"134_CR20","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1185\/030079907X219599","volume":"23","author":"L Pinto","year":"2007","unstructured":"Pinto L, Liu Z, Doan Q et al (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283\u20132295","journal-title":"Curr Med Res Opin"},{"key":"134_CR21","first-page":"715","volume":"10","author":"S Siena","year":"2003","unstructured":"Siena S, Piccart MJ, Holmes FA et al (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II\u2013IV breast cancer. Oncol Rep 10:715\u2013724","journal-title":"Oncol Rep"},{"key":"134_CR22","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.clinthera.2009.05.003","volume":"31","author":"GH Lyman","year":"2009","unstructured":"Lyman GH, Lalla A, Barron RL et al (2009) Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 31:1092\u20131104","journal-title":"Clin Ther"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0134-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-010-0134-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0134-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T11:13:36Z","timestamp":1591960416000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-010-0134-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,6]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1007\/s10147-010-0134-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,6]]}}}